Jaguar Gene Therapy
Dave brings 40 years of experience in the biopharmaceutical industry with global expertise in business development, marketing, and operations. His most recent role was CEO of Nightstar Therapeutics and currently serves on the board of Oxular ltd. and the Glaucoma Foundation.
This person is not in the org chart
This person is not in any offices
Jaguar Gene Therapy
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by the former AveXis leadership team and backed by Deerfield Management, a healthcare-specific investment firm, Jaguar brings streamlined R&D, manufacturing and clinical operations to accelerate development and potential approval of therapies for severe genetic diseases.